Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLife Solutions, Inc. (NASDAQ: BLFS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BioLife’s activities as a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review disclosures on BioLife’s Cell Processing, Cold Chain, and Thawing product areas, its focus on biopreservation media and related tools, and the financial impact of divestitures and strategic transactions. These filings also describe the company’s use of GAAP and non-GAAP metrics, its presentation of discontinued operations related to divested subsidiaries, and other elements of its financial reporting framework.
Current reports on Form 8-K highlight specific material events, including quarterly earnings announcements, investor presentations, and the sale of its evo cold chain logistics subsidiary. Proxy materials such as the definitive proxy statement (DEF 14A) provide insight into corporate governance, board composition, executive compensation proposals, and matters submitted to stockholder votes at the annual meeting.
On Stock Titan, each new BioLife filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in clear language. Users can quickly scan annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand changes in BioLife’s cell processing business, portfolio evolution, and governance decisions. The filings page also surfaces information relevant to topics such as equity awards and compensation policies discussed in proxy statements, helping investors interpret the regulatory record behind the BLFS stock.
BioLife Solutions reported stronger results for the quarter ended March 31, 2026, as revenue rose to $27.5 million, up $5.4 million or 25% from a year earlier. Growth was driven mainly by higher demand for its CryoStor biopreservation media.
Gross profit increased to $17.5 million, though gross margin slipped to 64% from 67% due to a less favorable product mix and more lower-margin products. Operating expenses rose 14% to $17.5 million, led by higher personnel costs and research and development tied to the PanTHERA acquisition.
The company moved from a net loss of $0.4 million to net income of $1.2 million from continuing operations, or $0.02 per diluted share. BioLife ended the quarter with $111.5 million in cash, cash equivalents, and available-for-sale securities and believes this is sufficient to fund operations for at least the next twelve months.
BioLife Solutions reported strong first quarter 2026 results, led by revenue of $27.5 million, up 25% from Q1 2025. GAAP gross margin was 64%, while GAAP net income from continuing operations rose to $1.2 million, or $0.02 per diluted share. Adjusted EBITDA reached $6.2 million, representing 22% of revenue.
Cash, cash equivalents, and marketable securities totaled $111.5 million as of March 31, 2026. The company reiterated 2026 guidance for revenue of $112.5–$115.0 million, implying 17–20% growth, with gross margin in the mid‑60% range, GAAP net income for the full year, and continued expansion of adjusted EBITDA margin.
Invesco Ltd. amended its Schedule 13G/A to report beneficial ownership of 2,348,532 shares of BioLife Solutions Inc. The filing states this equals 4.9% of the class, with 2,113,765 shares subject to sole voting power and 2,348,532 shares subject to sole dispositive power.
The amendment is signed by Invesco's Global Head of Compliance and dated 05/06/2026.
BioLife Solutions, Inc. filed Amendment No. 1 to its 2025 annual report to add detailed Part III information on directors, executive officers, governance and compensation instead of filing a proxy. The company reports 2025 revenue of $96.2 million, up from $74.6 million in 2024, and highlights focus on biopreservation media and cell processing tools.
BioLife completed the acquisition of PanTHERA CryoSolutions for about $11.5 million in cash plus $4.5 million in stock and divested SAVSU Technologies, generating about $23.3 million in cash. Named executive officer bonuses were tied to revenue, adjusted EBITDA margin, a clean 2025 annual report with no material weaknesses, and NetSuite MRP implementation, resulting in 2025 payouts at roughly 98% of target.
BioLife Solutions EVP and Chief Scientific Officer Mathew Aby J. reported a small share disposition related to taxes, not an open-market trade. On the release of restricted stock units, 515 shares of common stock were withheld by the company at $19.27 per share to satisfy his tax obligations. After this tax-withholding event, he directly holds 390,167 shares of BioLife Solutions common stock.
BIOLIFE SOLUTIONS INC Chief Marketing Officer Todd Berard reported a routine share disposition related to taxes. On the transaction date, 293 shares of common stock were withheld by the company to satisfy his tax withholding obligations that arose when restricted stock units were released. This was not an open-market sale. After this tax-withholding event, Berard directly held 163,768 shares of BIOLIFE SOLUTIONS INC common stock.
BioLife Solutions Inc. Chief Financial Officer Troy Wichterman had 844 shares of common stock withheld on April 8, 2026 to cover tax obligations from the release of restricted stock units. The shares were valued at $19.27 each, and he now directly holds 216,056 shares.
BioLife Solutions Inc. executive Karen A. Foster sold 2,577 shares of common stock in an open-market transaction. The sale occurred at a weighted average price of $19.17 per share and was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted effective December 4, 2025.
Following this transaction on March 23, 2026, Foster directly held 108,758 shares of BioLife Solutions common stock. The shares were sold in multiple trades at prices ranging from $18.99 to $19.35, and detailed breakdowns are available upon request as noted in the filing.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares of Common Stock, representing 0%, for BioLife Solutions Inc. The filing states an internal realignment on January 12, 2026 resulted in disaggregated reporting by subsidiaries; the amendment is signed on March 26, 2026.
BioLife Solutions Inc. President and CEO Roderick De Greef had 11,101 shares of Common Stock withheld to cover taxes on restricted stock units that vested. These shares were delivered back to the company as a tax-withholding disposition, not sold on the open market. Following this transaction, he directly holds 733,746 shares of BioLife Solutions common stock.